Focusing on automated in vitro diagnostics, "Fuji Bio" completed tens of millions of yuan in Series A financing

Focusing on automated in vitro diagnostics, “Fuji Bio” completed tens of millions of yuan in Series A financing

#Focusing #automated #vitro #diagnostics #Fuji #Bio #completed #tens #millions #yuan #Series #financing

It is reported that “Fu’s Bio” today announced the completion of tens of millions of yuan in Series A financing. This round of financing was invested by Jingze Capital, and the funds raised will be used for new product research and development and global marketing channel construction.

Founded in 2018, “Fu’s Bio” is a technology company whose main business is an automated in vitro diagnostic system platform. The current research and development direction covers cytology in vitro diagnosis, immunology in vitro diagnosis and other fields.

In vitro diagnosis refers to the detection of blood, body fluids, tissues, etc. of human samples to obtain clinical diagnostic information, and then determine diseases or body functions. Data show that in 2019, the global in vitro diagnostic market reached 71.4 billion U.S. dollars and reached 90 billion U.S. dollars in 2020. In 2019, China’s in vitro diagnostics market is about 80 billion yuan, and the compound annual growth rate from 2014 to 2019 is about 18.64%.

Picture from the company’s official website

“Fuji Bio” focuses on the R&D, manufacturing and integrated services of automated in vitro diagnostic product systems, forming two platforms.

The first is a fully automated immune cell and histochemical staining platform based on cell and tissue immunology. The platform can detect whether there is a target antigen in cells or tissues by coupling antibodies and using the specific binding reaction between antigens and antibodies in immunological principles. It can be used to measure the expression of antigens and also observe The location of the antigen.

The second is a fully automated POCT (also known as point-of-care testing) in vitro diagnostic platform based on molecular immunology, also known as “bedside testing”, which can save the complicated processing procedures of specimens in laboratory testing , Get test results quickly.

The earliest entry point of “Fu’s Bio” is the early screening and diagnosis of cervical cancer. At the beginning of last year, KS9600, the first system of fully automated immune cell/histochemistry diagnostic and screening product of “Fu’s Bio”, obtained the registration certificate and entered the clinical market expansion period, and began to develop supporting reagents. This product detects the expression of the two genes P16 and Ki67 in the protein to determine whether cervical exfoliated cells have precancerous lesions. This test method is jointly recommended by the Besthesda Guidelines, the American Society of Pathology (CAP) and the American Society of Colposcopy and Pathology (ASCCP). Compared with the traditional cervical cancer early screening system, this system can shorten the detection time from 1-2 days to 2 hours. The fully automated staining technology also helps pathologists improve their work efficiency, and the detection accuracy rate is as high as 95%.

According to Lian Zhengxin, the founder of “Feishi Biology”, the in vitro diagnostic system has been extended to nearly 100 domestic hospitals and physical examination centers, 80% of which are top-tier hospitals. Recently, the second-generation automatic immunocytochemical staining system was launched. Compared with the first generation launched last year, this product has increased sample throughput and improved detection speed.

In response to the new crown epidemic, at the beginning of 2020, “Fish Bio” quickly developed the “automatic new crown antibody detection and S-RBD verification kit”. This kit can not only detect whether the subject has ever been infected with the new crown virus. History, you can also further test the quantitative effect of S-RBD antibody produced after the vaccine injection. At the same time, the serum total antibody detection method adopted by this product is the methodology recommended by the WHO, which is suitable for large-scale population antibody detection. In June 2020, the test reagent entered the “white list” of the China Chamber of Commerce for Import and Export of Medicines and Health Products, and obtained access qualifications from many countries. At present, the products have been applied for registration certificates in many countries in Europe and America, and the domestic registration certificates are also being applied. Lian Zhengxin believes that this kit will be a very important supplement in the post-epidemic era.

Editor: Cai Shuning


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *